Form 4: Inari Medical CEO Andrew Hykes Sells Shares Under 10b5-1 Trading Plan

Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at an average price of $55.23, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 22, 2024, Andrew Hykes, the President and CEO of Inari Medical, Inc., sold 3,000 shares of common stock.
• The sale was executed at a weighted average price of $55.23 per share, with individual trades ranging from $54.92 to $55.59.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 13, 2023.
• Following the transaction, Hykes directly owns 455,252 shares of Inari Medical common stock.
• Hykes also indirectly owns 1,550 shares through each of his three children and 1,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily indicate a change in the executive's confidence in the company.

Industry Context

Executive stock sales are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the effect is likely to be minimal given the pre-planned nature of the sale.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates